Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Fig. 3

Kaplan–Meier curve of PFS in subgroups defined by the presence/absence of negatively impacting biomarkers.*

*Biomarkers were considered negatively prognostic of response to HER2-targeted treatment based on their association with a numerical decrease in PFS. Specifically, these included expression of mutated PIK3CA, low HER2 mRNA level (≤median), and focal HER2 distribution. Patients without negative markers were those with nonmutated PIK3CA, high HER2 mRNA levels (>median), and non-focal (i.e., heterogeneous or homogenous) distribution of HER2. Patients with negative markers were those with mutated PIK3CA, low HER2 mRNA levels (≤median), and focal HER2 distribution. HER2 human epidermal growth factor receptor 2, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, PFS progression-free survival, T-DM1 trastuzumab emtansine

Back to article page